Organogenesis (NASDAQ:ORGO – Get Free Report) and Gain Therapeutics (NASDAQ:GANX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.
Earnings and Valuation
This table compares Organogenesis and Gain Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Organogenesis | $564.17 million | 0.61 | $37.03 million | ($0.19) | -14.11 |
| Gain Therapeutics | $50,000.00 | 1,569.52 | -$20.16 million | ($0.58) | -3.17 |
Profitability
This table compares Organogenesis and Gain Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Organogenesis | -0.84% | 9.63% | 4.76% |
| Gain Therapeutics | N/A | -201.44% | -136.24% |
Volatility & Risk
Organogenesis has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Organogenesis and Gain Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Organogenesis | 1 | 2 | 1 | 0 | 2.00 |
| Gain Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
Organogenesis presently has a consensus target price of $5.75, indicating a potential upside of 114.55%. Gain Therapeutics has a consensus target price of $7.50, indicating a potential upside of 307.61%. Given Gain Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Organogenesis.
Institutional and Insider Ownership
49.6% of Organogenesis shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 18.8% of Organogenesis shares are held by insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Organogenesis beats Gain Therapeutics on 8 of the 14 factors compared between the two stocks.
About Organogenesis
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
About Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.
